UNSPSC 51313419: Brompheniramine tannate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C76H52O46.C16H19BRN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NQD5087V38. European Medicines Agency schedules brompheniramine tannate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20623. Most nations, for tariff and trade purposes, schedule brompheniramine tannate under HS 29333999 and SITC 51574. SMILES: As of Q4 2014, BROMPHENIRAMINE TANNATE remains US FDA's Preferred Term for this commodity.

UNSPSC 51313419 Brompheniramine tannate is a Commodity code that nominally covers a single antihistamine product, but the recent state and local procurement activity tagged under it shows little relevance to brompheniramine tannate specifically. The three most recent opportunities — a Seminole County naloxone and drug deactivation systems procurement, a Texas HHS direct-to-manufacturer prescription program RFI, and a Minnesota multistate cooperative purchasing alliance RFP for generic pharmaceuticals and OTC products — address naloxone, pharmacy benefit management, and broad generic drug sourcing respectively. None target brompheniramine tannate as a line item or focal product. The issuing bodies span county health departments, state health and human services agencies, and cooperative purchasing organizations, but the code's narrow commodity scope does not align with the generalist pharmaceutical and OTC procurement activity currently being solicited under it.

Geographic activity appears concentrated in the South and Upper Midwest — Seminole County, Florida; Texas; and Minnesota — though the Minnesota solicitation extends to Oregon through MMCAP's multistate participation. The Seminole County IFB (IFB60459723LAS) closed on July 26, 2023, the Texas HHS RFI (HHS0017013) posted April 3, 2026, and the MMCAP RFP (S1070000015802) closed March 26, 2026. The mismatch between the code's name and the actual procurement scope suggests tagging error rather than active state and local demand for brompheniramine tannate as a discrete pharmaceutical commodity.